57573-59-8

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-3-methylquinazolin-4(3H)-one is used as a building block for the synthesis of pharmaceutical agents and bioactive molecules, leveraging its potential biological and pharmacological activities.
Used in Medicinal Chemistry Research:
6-Bromo-3-methylquinazolin-4(3H)-one is utilized as a valuable target in medicinal chemistry research, where its structure and properties are explored for the development of new drugs with anti-tumor and anti-inflammatory effects.
Used in Drug Development:
6-Bromo-3-methylquinazolin-4(3H)-one is employed in drug development for its potential to contribute to the creation of novel therapeutic agents, particularly those aimed at treating cancer and inflammatory conditions. Its unique chemical structure allows for the design of molecules that can target specific biological pathways involved in these diseases.

InChI:InChI=1/C9H7BrN2O/c1-12-5-11-8-3-2-6(10)4-7(8)9(12)13/h2-5H,1H3

Upstream product

• 123-39-7 N-Methylformamide 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 
• 134-20-3 2-carbomethoxyaniline 
• 32084-59-6 6-bromoquinazolin-4(3H)-one 
• 74-88-4 methyl iodide 
• 4692-98-2 5-bromoisatoic anhydride 
• 74-89-5 methylamine 
• 91-56-5 indole-2,3-dione 
• 6214-20-6 methyl 4-nitrobenzenesulfonate 
• 32084-59-6 6-bromo-4-hydroxyquinazoline 

Downstream Products

• 1209485-71-1 3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-4(3H)-one 
• 1396310-25-0 N-(2-chloro-4-fluoro-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)propane-1-sulfonamide 
• 1396310-22-7 N-(2,4-difluoro-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)propane-1-sulfonamide 
• 1396310-72-7 N-(4-chloro-2-cyano-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)propane-1-sulfonamide 
• 1396310-74-9 N-(2-cyano-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)propane-1-sulfonamide 
• 1396310-24-9 N-(2,4-difluoro-3-(methyl(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)phenyl)propane-1-sulfonamide 
• 1396310-84-1 N-(4-chloro-2-fluoro-3-(methyl(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)phenyl)propane-1-sulfonamide 
• 1396310-29-4 N-(2-chloro-4-fluoro-3-(methyl(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)phenyl)propane-1-sulfonamide 
• 1396311-05-9 N-(3-(ethyl(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-2,4-fluorophenyl)propane-1-sulfonamide 
• 1396311-03-7 N-(2-chloro-3-(ethyl(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)propane-1-sulfonamide 
• 16064-23-6 6-amino-3-methylquinazolin-4-one 

Relevant academic research and scientific papers

SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT

This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.

Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition

Aurora A kinase, a member of the Aurora kinase family, is frequently overexpressed in various human cancers. In addition, Overexpression of Aurora A kinase is associated with drug resistance and poor prognosis in many cancers including breast cancer. Therefore, Aurora A kinase has been considered as an attractive anticancer target for the treatment of human cancers. Herein, A series of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives were designed, synthesized, and evaluated as Aurora A kinase inhibitors. The cell-based cytotoxicity assays showed that compound 16h was the most potent cytotoxic agent against all tested cancer cells and had a lower IC50 value than ENMD-2076 against MDA-MB-231 cells. Meanwhile, Aurora A kinase assay and Western blot analysis showed that 16h inhibited Aurora A kinase with an IC50 value of 21.94 nM and suppressed the phosphorylation of Histone H3 on Ser10 and Aurora A kinase on Thr288, which were consistent with the activation of Aurora A kinase. Accordingly, 16h caused aberrant mitotic phenotypes and obvious G2/M phase arrest in MDA-MB-231 cells and induced caspase-dependent apoptosis in MDA-MB-231 cells. These results demonstrated that 16h is a potential candidate for the development of anticancer agents targeting Aurora A kinase.

Synthesis and biological evaluation of some amino- and sulfanyl-3H-quinazolin-4-one derivatives as potential anticancer agents

A series of 6-substituted quinazolinone derivatives were prepared by the reaction of 6-bromoquinazolinones with aryl or alkyl amines and thiols, in the presence of a Pd(OAc)2/Xantphos system, under Buchwald-Hartwig-type reaction conditions. The 6-bromoquinazolinones were obtained in the three-components reaction of 5-bromoisatoic anhydride, triethyl orthoformate and an appropriate amine. Biological screening of the potential cytotoxicity of synthesized compounds on HT29 and HCT116 cell lines, as well as on the lymphocytes, showed that some derivatives of quinazolinone have significant anticancer activities. The detailed synthesis, spectroscopic data, and biological assays were reported.

CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR

The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by nicotinic acetylcholine receptors, such as schizophrenia and Alzheimer's disease.

BICYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to novel Bicyclic Heterocyclic Derivatives, pharmaceutical compositions comprising the Bicyclic Heterocyclic Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

QUINAZOLINONE DERIVATIVES HAVING B-RAF INHIBITORY ACTIVITY

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY

The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS

The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.